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28 BULLETED STATEMENTS
29  Currently, there are few studies that evidence specific changes of the placental metabolic 
30 profile during the first trimester of pregnancy. 
31  This study analyzes alterations in placental metabolites composition in euploid and 
32 aneuploid cases. Polyols might have a crucial role in energy production. In aneuploid cases 
33 the exceeding activation of polyol pathway leads to the increase of oxidative stress. Myo-
34 inositol and cholesterol decrease in cases of aneuploidy.
35 Bulleted statement
36  Switch from anabolic to catabolic placental metabolism during the first trimester is a typical 
37 feature of pregnancy to promote fetal growth, but only few scientific studies evidenced 
38 specific changes of the placental metabolic profile during this pregnant period. Changes in 
39 maternal metabolic composition, has been observed by the analysis of biofluids and similar 
40 changes could be observed also in placenta tissue suggesting biological mechanisms in 
41 normal and pathological pregnancies
42  This study allowed to better understand alterations in placental metabolites composition in 
43 euploid and aneuploid cases. Key findings of this study evidenced that in normal pregnancy 
44 polyols might have a crucial role in energy production. In aneuploid cases the exceeding 
45 activation of polyol pathway leads the increase of oxidative stress. Moreover, myo-inositol 
46 and cholesterol were found decresed in cases of aneuploidy compared to euploidy at the 
47 same gestational age.
48
49
50
51 KEY WORDS: Placental development; Chorionic villous; Trisomies; Metabolomics; Polyol 
52 Pathway; Oxidative stress.
53
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54 ABSTRACT
55
56 Objective: Placenta-related biological samples are used in biomedical research to investigate 
57 placental development. Metabolomics represents a promising approach for studying placenta 
58 placental metabolism in an effort to explain physiological and pathological mechanisms. The aAim 
59 of the this study was to investigate metabolic changes in chorionic villous villi during the first 
60 trimester of pregnancy in euploid and aneuploid cases.
61 Methods: Samples from 21 women (13 euploid, 8 aneuploid) were analyzed with 1H-Nuclear 
62 Magnetic Resonance (NMR), Gas Chromatography-Mass Spectrometry (GC-MS) and High-
63 Performance Liquid chromatography (HPLC). Multivariate statistical analysis was performed and 
64 differences in metabolites were used to identify the altered metabolic pathways.
65 Results: A regression model to test the correlation between CRL fetal crown-rump length (CRL) 
66 and metabolic profile of chorionic villous was performed in euploid pregnancies (R2 was 0.69 for 
67 the NMR analysis and 0.94 for the GC-MS analysis). Supervised Analysis was used to compare 
68 chorionic villi of euploid and aneuploid fetuses (NMR: R2X=0.70, R2Y=0.65, Q2=0.30 R2X=0.62; 
69 GC-MS: R2Y=0.704, Q2=0.444). Polyol pathways, myo-inositol and oxidative stress seem to have a 
70 fundamental role in euploid and aneuploid pregnancies. 
71 Conclusion: Polyol pathways may have a crucial role in energy production in early pregnancy. 
72 Excessive activation in aneuploid pregnancies may lead to increased oxidative stress. Metabolomics 
73 represents a promising approach to investigate placental metabolic changes.
74
75
76
77
78
79
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80 INTRODUCTION
81 Placenta-related biological samples are used, in biomedical research, to investigate normal placental 
82 development, biology and pathophysiology1. In pregnancy, many changes in placenta development 
83 occur at the end of the first trimester2,3:  the oxygen tension within the intervillous space increases 
84 from 2.5% at 8 weeks to 8.5% at 12 weeks4; the maternal metabolic profile changes from anabolic 
85 to catabolic metabolism to promote fetal growth, maturation and development5,6,7. During this 
86 gestational period, changes in maternal metabolic composition have, has been observed by the 
87 analysis of biofluids8 and similar changes could can also be observed also in placenta placental 
88 tissue. This suggests suggesting physiologic mechanisms in both normal pregnancies and 
89 pathological changes as well, such as in cases of aneuploidy. Metabolomics represent a promising 
90 approach in the understanding of  the placental metabolism. Analytical techniques such as mass 
91 spectrometry (MS)9 and nuclear magnetic resonance (NMR)10 can provide information about tissue 
92 metabolites, such as lipids, amino acids and high-energy metabolites. This could identifiedcan 
93 identify altered metabolic pathways11 providing a “snapshot” of the metabolic profile during 
94 different conditions12,13,14 and employing pattern recognition techniques15.
95 The metabolic profile of the placenta in early pregnancy is still poorly characterized16. Several 
96 studies identified differences in metabolomic profiles of serum markers in pregnant women with 
97 fetal chromosomal disorders17,18,19 but, to our knowledge, no study has been performed on chorionic 
98 villi collected after Transabdominal Chorionic Villus Sampling (TA-CVS). 
99 The aim of our study was to evaluate differences in first trimester placenta metabolic pattern 
100 between euploid and aneuploid pregnancies through a metabolomic analysis of chorionic villi, 
101 obtained by TA-CVS. 
102
103 METHODS
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104 This prospective study was conducted in the Department of Prenatal Diagnosis in the 
105 Microcitemico Pediatric Hospital in Cagliari, Sardinia. All patients underwent first-trimester 
106 combined screening for aneuploidy between 11 weeks to 13 weeks and 6 days gestational age. First 
107 trimester combined test screening produces individualized risk estimates for trisomies 21, 18, and 
108 1320 based on maternal age, ultrasound (used to document fetal nuchal translucency (NT) and fetal 
109 crown rump length (, CRL)) and biochemical parameters (maternal blood sampling determines 
110 biochemical markers including pregnancy-associated plasma protein A, PAPP-A, and free beta 
111 human chorionic gonadotropin, β-hCG). Combined screening is considered the most accurate 
112 method to produce an individual risk of aneuploidy and provides a  detection rate of 95% and a 
113 false positive rate of 2.5%21. A cut-off risk of 1:250 for aneuploidies is high risk according to the 
114 Italian Society of Obstetric Gynecological Ultrasound (SIEOG)22. Such patients undergo genetic 
115 counseling and prenatal invasive diagnostic tests are offered. 
116 All TA-CVS were performed between the 11th to and 14th week of pregnancy gestation by free-hand 
117 transabdominal technique by a single operator (GM)23. Written consent was obtained from all 
118 participating women, approved by Institutional Review Board of Microcitemico Hospital. After 
119 sampling, an adequate specimen of chorionic villi was used for cytogenetic examination and a 
120 remaining aliquot reserved for metabolomics analysis, was frozen immediately (< 2 minutes) in 
121 liquid nitrogen and kept at -80°C until use.
122 Patient demographics (ethnic group, age), ultrasound data (e.g CRL, NT measurement), 
123 biochemical parameters (free β-hCG and PAPP-A) and fetal karyotype were collected.
124 Samples were divided into two groups based on the outcome of the karyotype: euploid fetuses 
125 (n=13, group EUPC) and aneuploid fetuses (n= 8, CHRgroup  ANEUP). Aneuploidies The 
126 aneuploid group included trisomy 21 (n=4), trisomy 18 (n=2) and  trisomy 13 (n=2). Control 
127 patients were enrolled by choosing only those who underwent TA-CVS based only on their age 
128 (>35years). Moreover, some patients in the control group were offered an invasive procedure 
129 through genetic counselling because they had a history of a fetus with a chromosomopathy in a 
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130 previous pregnancy.  Patients showing abnormal combined screening test were not included in the 
131 control group. The metabolomic profile of C group EUP and CHR group ANEUP  were then 
132 compared. The different aneuploidies were compared with each other and with the Control control 
133 Groupgroup.
134 Sample preparation
135 To standardize the protocol, we used the same amount of extraction solvent for all the samples. 
136 Briefly, CVS samples were mixed with 800 µL of methanol and 200 µL of Milli-Q water and then 
137 vortexed for 1 minutesminute. After 30 minutes of sonication in water with ice (Digital ultrasonic 
138 Cleaner, DU-32, Argo-Lab, Italy) samples were kept at -20°C for 20 minutes and then centrifuged 
139 at 8,600gfor 10 min at 4°C. The supernatant containing low molecular weight compounds (e.g. 
140 sugars, fatty acids, amino acids) was collected for the metabolomics analysis. Concentrations of the 
141 metabolites in the samples were normalized after the analysis with NMR or GC-MS. Aliquots 
142 (10µl) from each sample were used to create a pool for quality control (QC) samples. A QC sample 
143 was injected at the beginning and at the end of the analysis. Subsequently, PCA (Principal 
144 Component Analysis) model was performed including the QC samples and based on their tight 
145 clustering , it showed a good quality of the analysis in our batch
146 Nuclear Magnetic Resonance analysis and data processing
147 For the NMR analysis, 600 µL of the water-phase for each sample was dried overnight in a speed-
148 vacuum. The dried water-phase was re-suspended in 697 µl of phosphate buffer 100 mM in D2O, 
149 pH 7.3 and 3µl of trimethylsilylpropanoic acid (TSP) 5.07 mM. TSP was added to provide an 
150 internal reference for the chemical shifts (0 ppm), and 650 µl of the solution were transferred to a 5 
151 mm NMR tube. 
152 The samples were analyzed with a Varian UNITY INOVA 500 spectrometer (Agilent 
153 Technologies, Inc., Santa Clara, CA, USA), which was operated at 499 MHz equipped with a 5 mm 
154 triple resonance probe with z-axis pulsed field gradients and an auto-sampler with 50 locations. 
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155 One-dimensional 1H-NMR spectra were collected at 300 K with a pre-sat pulse sequence. The 
156 spectra were recorded with a spectral width of 6000 Hz; a frequency of 2 Hz; an acquisition time of 
157 1.5 s; a relaxation delay of 2 ms; and a 90° pulse of 9.5 µs. The number of scans was 512. Each 
158 Free Induction Decay (FID) was zero-filled to 64 k points and multiplied by a 0.5 Hz exponential 
159 line-broadening function. The spectra were manually phased and baseline corrected. By using 
160 MestReNova software (version 8.1, Mestrelab Research S.L.) each NMR spectrum was divided into 
161 consecutive “bins” of 0.04 ppm. The spectral area investigated was the region between 0.8 and 8.6 
162 ppm. To minimize the effects of the different concentrations of chorionic villus samples, the 
163 integrated area within each bin was normalized to a constant sum of 100. The final data set 
164 consisted of a 155x21 matrix. 
165 Gas-Chromatography Mass-Spectrometry analysis and data processing
166 For GC-MS analysis, 300 µL of each extract were dried with a vacuum concentrator overnight 
167 (Eppendorf concentrator plus, Eppendorf AG, Hamburg, Germany)and were derivatized with 25 μL 
168 of methoxyamine dissolved in pyridine (10 mg/mL) (Sigma-Aldrich, St. Louis, MO, USA) at 70°C. 
169 After 1 h, 50 μL of N-Methyl-N-(trimethylsilyl)-trifluoroacetamide, (MSTFA, Sigma-Aldrich, St. 
170 Louis, MO, USA) was added and samples were left at room temperature for one hour. Samples 
171 were diluted in 50 μL of hexane (Sigma-Aldrich, St. Louis, MO, USA) and one microliter of 
172 derivatized sample was injected splitless into a 7890A gas chromatograph coupled with a 5975C 
173 Network mass spectrometer (Agilent Technologies, Santa Clara, CA, USA) equipped with a 30 m 
174 ×0.25 mm ID, fused silica capillary column, with a 0.25 μM TG-5MS stationary phase (Thermo 
175 Fisher Scientific, Waltham, MA, USA). The injector and transfer line temperatures were at 250°C 
176 and 280°C, respectively. The gas ﬂow rate through the column was 1 ml/min. The column initial 
177 temperature was kept at 60 °C for 3 min, then increased to 140°C at 7°C/min, held at 140°C for 4 
178 min, increased to 300°C at 5°C/min and kept for 1 min. For the analyzed samples we extracted 
179 masses from a range 50-600 m/z. Identification of metabolites was performed using the standard 
180 NIST 08 (http://www.nist.gov/srd/mslist.cfm), Fiehn 2013 (http://fiehnlab.ucdavis.edu/Metabolite-
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181 Library-2007) and GMD (http://gmd.mpimp-golm.mpg.de) mass spectra libraries (match ≥ 40%) 
182 and, when available, by comparison with authentic standards. Data processing was performed by 
183 using a pipeline in Knime24KNIME24. In brief, peak detection and deconvolution were performed in 
184 a R-XCMS package, filtering was performed using blank samples and keeping features present in 
185 ≥50% of the samples. Missing value imputation was conducted by using random forest algorithm. 
186 Relative concentrations of the discriminant metabolites were obtained by the chromatogram area 
187 and then normalized by median fold change. All the parameters were reported in supplementary 
188 materials.
189 Determination of intracellular aminothyol levels
190 Glutathione reduced and oxidized (GSH, GSSG) and ascorbic acid levels were determined in 
191 chorionic villi, using a modified method described by Khan et al25. Samples were dissolved in 150 
192 μl of 10% meta-phosphoric acid solution. After vortexing for 2 minutes, 150 μl of 0.05% TFA 
193 (trifluoroacetic acid) solution was added and centrifuged for 10 min at 10000 rpm at 4 °C. An 
194 aliquot was transferred in to an Eppendorf tube for the determination of the proteins through 
195 Bradford Assay. The supernatant was injected into the HPLC system (Agilent 1260 infinity, Agilent 
196 Technologies, Palo Alto, USA). GSH, GSSG and ascorbic acid levels were measured by 
197 electrochemical detection26, using an HPLC coupled with an electrochemical detector (DECADE II 
198 Antec, Leyden, The Netherlands) and an Agilent interface 35900E. A C-18 Phenomenex Luna 
199 column, 5 μm particle size, 150×4.5 mm, was used with a mobile phase of 99% water with 0.05% 
200 TFA (v/v) and 1% MeOH at a flow rate of 1 ml/min. An eElectrochemical detector was set at an 
201 oxidizing potential of 0.74 V. Data were collected and analysed using the Agilent Chemstation 
202 A.10.02 Software, and expressed as area of GSH, GSSG and ascorbic acid peak to μg of proteins.
203 Statistical analysis
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204 Multivariate statistical analysis was performed on NMR and GC-MS data by using SIMCA-P 
205 software (ver. 14.0, Umetrics, Sweden)27. The variables were Pareto scaled for the 1H-NMR 
206 analysis and UV scaled for the GC-MS analysis.
207 The initial data analyses were conducted using the Principal Component Analysis (PCA) for the 
208 exploration of the sample distributions without classification. To identify potential outliers, the 
209 DmodX and Hotelling’s T2 tests were applied. 
210 A supervised analysis was subsequently used. Orthogonal Partial Least Square (OPLS-DA) analysis 
211 and Partial Least Square (PLS-DA) maximize the discrimination between samples assigned to 
212 different classes. The variance and the predictive ability (R2X, R2Y, Q2) were established to 
213 evaluate the suitability of the models. Since VIP (Variable Influence on Projection) >1 are the most 
214 relevant for explaining Y (assignment of two classes)27, our OPLS-DA model for the NMR matrix 
215 and PLS-DA models for the GC-MS matrix were performed by using only variables corresponding 
216 to VIP value >1. In addition, a permutation test (n = 400) was performed to validate the models. 
217 The scores from each PLS-DA model were subjected to a CV-ANOVA to test for significance 
218 (p<0.05). To study a possible linear relationship between a matrix Y (dependent variables, e.g. 
219 clinical parameters such as length of the fetus) and a matrix X (predictor variables, e.g. metabolites) 
220 Partial Least Squares projection to latent structures regression (PLS) model was performed28.
221 The most significant variables were extracted by the loading plot from the PLS-DA model and from 
222 the S-plot from the OPLS-DA model and for the 1H-NMR data were identified using the Chenomx 
223 NMR Suite 7.1 (Chenomx Inc., Canada)29 and on literature data. GraphPad Prism software (version 
224 7.01, GraphPad Software, Inc., CA, USA) was used to perform the univariate statistical analysis of 
225 the data resulting from the multivariate analysis and from the HPLC analysis. To verify the 
226 significance of the metabolites, resulting a U-Mann Whitney test was performed. 
227
228 Pathways analysis 
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229 Metabolic pathways were generated by using MetaboAnalyst 3.030, a web server designed to obtain 
230 a comprehensive metabolomic data analysis, visualization and interpretation31. This approach 
231 permits correlation of metabolite changes with metabolic networks. The pathway analysis module 
232 of Metaboanalyst 3.030,31 uses the high-quality KEGG metabolic pathways as the backend 
233 knowledgebase. Literature was also used to identify the most important pathways involved.
234 RESULTS
235 Metabolic changes in association with CRL
236 In this study, 21 samples of chorionic villi (13 controls euploid  and 8 aneuploid) were analyzed 
237 with 1H-NMR and HPLC while 17 (9 controls, 4 controls samples were not analyzed for lack of 
238 biological sample, and 8 chromosomal disorders) were analyzed by GC-MS. The number of 
239 metabolites identified were: 47 with 1H-NMR and 28 with GC-MS, including organic acids, amino 
240 acids, fatty acids and sugars (Fig. 1 A-B).
241 To investigate a possible correlation between the metabolic profile of chorionic villous in euploid 
242 pregnancies and the CRL (a specific marker of gestational age), PLS regression analysis was 
243 performed (Fig. 2 A-B) using the matrices resulting from both NMR and GC-MS analysis. 
244 The correlation analysis showed a R2 = 0.69 for the NMR analysis and R2 = 0.94 for the GC-MS 
245 analysis. The correlation between the NMR-metabolic profile and the CRL parameter indicated a 
246 linear positive correlation with increasing concentrations of myo-inositol, glutamine and citrate. 
247 Looking at the distribution of metabolites in the analysis of the GC-MS matrix, there was a positive 
248 linear correlation with the concentration of myo-inositol, inositol, glycerol, dehydroascorbic acid 
249 and ribitol, while an inverse correlation with the concentration of xylitol, 1,5-anydro-D-Sorbitol, D-
250 fructose and D-mannose was observed.
251 Metabolic fingerprinting of chromosomal disorders 
252 Subsequently, to investigate any differences between euploid and aneuploid samples of the same 
253 gestational age, a PLS-DA analysis was performed (Fig. 2 C-D) and the obtained model showed the 
254 following statistical parameters: R2X=0.70, R2Y=0.65, Q2=0.30, for the NMR analysis (Fig. 2C) 
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255 and R2X=0.60, R2Y=0.75, Q2=0.47 for the GC-MS analysis (Fig. 2D). The models were then 
256 validated with the permutation test, (for the NMR, R2 intercept = 0.428; Q2 intercept = -0.12, for the 
257 GC-MS, R2 intercept = 0.47; Q2 intercept = -0.6). 
258 The multivariate analysis identified a unique pattern of metabolites in the aneuploid chorionic villi. 
259 In particular, NMR analysis displayed an increase of lactate, asparagine, branched-chain-
260 aminoacids (valine, leucine and isoleucine) and a decrease of myo-inositol, glycerol, fumarate, 
261 betaine and acetate in CHR group ANEUP compared to group EUPC. At the same time, GC-MS 
262 analysis showed that eleven metabolites were responsible for the separation between the groups. In 
263 particular, D-sorbitol, 1,5-anydro-D-sorbitol, D-fructose, dehydroascorbic acid and glucose were 
264 increased in CHR Groupgroup ANEUP, while cholesterol, pyruvic acid, palmitic acid, inositol, 
265 homoserine and stearic acid were decreased. The bar graphs representing the mean concentration of 
266 the metabolites and the relative standard deviations are shown in Fig. 3.
267 The metabolites having with VIP value > 1 resulting from the multivariate analysis, were used to 
268 identify the most important metabolic pathways involved in chromosomal diseases(Fig. 4A). 
269 The most perturbed pathways were involved in energetic processes, such as glycolysis and 
270 gluconeogenesis, pentose phosphate shunt, pyruvate metabolism and TCA cycle. Statistical 
271 parameters of the pathways analysis (p-value, n° metabolites involved for each pathway) are 
272 reported in Table 1S. Several of the metabolites which differed in the multivariate analysis were 
273 involved in the polyol pathway (glucose, fructose, sorbitol), suggesting a hypothetic role of this 
274 process in chromosomal disorders (Fig. 4B).
275 The excessive activation of the polyol pathway proposed in CHRgroup ANEUP, suggests the 
276 presence of an oxidative stress environment. This data was confirmed with the analysis of the amino 
277 thiols levels: GSH and GSSG, appear to decrease in CHRgroup ANEUP. A similar observation was 
278 found for ascorbic acid level, which was significantly lower in CHR group ANEUP (Fig. 3B).
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279 Subsequently, to understand the metabolic differences between controls and each individual 
280 aneuploidy, supervised PLS-DA models were performed both with the data of NMR (data not 
281 shown) and GC-MS (Fig. 5A). Statistical parameters were: C group EUP vs Trisomy 21 (group 
282 EUP=7, Trisomy 21=4), R2X=0.62, R2Y=0.887, Q2=0.441, (permutation test : R2 intercept = 0.79; 
283 Q2 intercept = 0.06);, C group EUP vs Trisomy 18 (group EUP=7, Trisomy 18=2): R2X=0.509, 
284 R2Y=0.940, Q2=0.431 (permutation test : R2 intercept = 0.78; Q2 intercept = 0.05), C group EUP vs 
285 Trisomy 13 (group EUP=7, Trisomy 13=2): R2X=0.557, R2Y=0.868, Q2=0.399 (permutation test : 
286 R2 intercept = 0.77; Q2 intercept = 0.01). Based on the PLS-DA models, aA global overview of the 
287 different metabolic profiles of the three chromosomal diseases is summarized in Fig. 5B. The 
288 results show the overall potential of the metabolomics approach; however, due to the small number 
289 of samples for each individual aneuploidy, additional study is necessary (as evidenced by the 
290 permutation tests).
291 DISCUSSION
292
293 In this study, a metabolomics approach was appli d to describe the normal metabolic status of 
294 placenta in the first trimester of pregnancy and to compare euploid and aneuploid chorionic villi 
295 samples. Despite the low number of the samples (due to the fact that it is not easy to enroll a large 
296 number of patients with aneuploid fetuses affected by trisomies is not easy), chorionic villous 
297 samples, collected for the karyotype analysis, were analyzed through three different analytical 
298 techniques (NMR, GC-MS and HPLC) in order to have an overview of the placenta metabolome as 
299 complete as possible. Pregnancy is a period characterized by several physiological changes in 
300 metabolic, biochemical, hormonal and immunological status32. For this reason, metabolic alterations 
301 of chorionic villus in the crucial period between the 11th to 14th week of pregnancy, were 
302 investigated.
303 Metabolic changes in association with CRL
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304 Normal pregnancies are characterized by changes in the levels of haematological circulating free 
305 fatty acids, triglycerides, cholesterol and phospholipids and a insulin resistance33. These metabolic 
306 changes represent a necessary and indispensable adaptation to satisfy the fetal energy demands 
307 necessary for rapid growth and to prepare the maternal body system for delivery and lactation34. 
308 Insulin resistance, a physiologic change during pregnancy, is the basis of this metabolic maternal 
309 adaptation to ensure adequate fetal carbohydrate supply.  
310 As pregnancy advances, insulin sensitivity gradually declines to 50%35 due to hormones (estrogen, 
311 progesterone) and the activity of other factors, such as inositol and myo-inositol36. Inositol and myo-
312 inositol are intracellular mediators of the insulin signal; theyand are correlated with insulin 
313 sensitivity and , indeed they could be implicated in glucose homeostasis37,38,39.
314 Our results demonstrated changes in the concentrations of some metabolites in chorionic villi 
315 correlating with the fetus length. Particularly, myo-inositol and inositol levels linearly correlate with 
316 the CRL, both in the NMR and GC-MS analysis, suggesting a biological role during pregnancy. 
317 The correlation of these metabolites with CRL supports involvement in glucose homeostasis as 
318 several studies have previously reported33.
319 Cholesterol levels in chorionic villi, as well as myo-inositol and inositol, were increased in 
320 correlation with the CRL. The higher concentration of cholesterol may the result of increased levels 
321 of pro-gestational hormones. In fact, in maternal blood cholesterol represent represents the 
322 precursor of both progesterone and estrogen40.
323 Aminoacids are essential factors for fetal development and growth. T, they arerepresent the 
324 precursors for the biosynthesis of macromolecules (proteins and nucleotides), signalling functions 
325 and Adenosine triphosphate (ATP) production41. In our data, glutamine showed a linear correlation 
326 with the CRL and gestational age.  Glutamine is involved in numerous physiological metabolic 
327 pathway of the fetus42,43. It is a substrate for protein synthesis and an anabolic precursor for muscle 
328 growth. Glutamine is a precursor for neurotransmitters, for nucleotide and nucleic acid synthesis 
329 and for glutathione production41,43.
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330 Finally, our data revealed that there is an increased concentration of xylitol, 1,5-anydro-D-sorbitol, 
331 D-fructose and D-mannose in the early stages of the first trimester of pregnancy. These metabolites 
332 are known to be involved in the polyol pathway, which is susceptible to glucose concentration. 
333 Polyols are polyhydric alcohols formed by the reduction of aldoses and ketoses, and their precursors 
334 are essential substrates for the glycolytic and pentose phosphate pathways. It has been hypothesized 
335 that polyols are the first source of carbohydrates for early life44 and this could explain the high level 
336 of these metabolites seen in our first trimester placenta samples. 
337 The polyol pathway starts with glucose, which normally enters into glycolysis to produce pyruvic 
338 acid and acetyl-CoA. Insulin is one of the key regulators of metabolism45. Indeed, maternal insulin 
339 resistance plays an important role in the regulation of maternal energy metabolism, fat deposit and 
340 fetal growth46,47. In a hyperglycemic environment, increased intracellular glucose results in its 
341 increased enzymatic conversion to the polyalcohol sorbitol, with a concomitant decrease in 
342 NADPH. NADPH is required for regenerating reduced glutathione (GSH) and this might induce or 
343 exacerbate intracellular oxidative stress48.
344 Furthermore, in the first trimester of pregnancy, the oxygen tension within the intervillous space 
345 increases from 2.5% at 8 weeks to 8.5% at 12 weeks2. Metabolism of the placenta tissue appears to 
346 adapt to these conditions through the activation of the polyol pathway. This pathway could provide 
347 an important mechanism for the re-oxidation of pyridine nucleotides under conditions of low 
348 oxygenation, enabling glycolysis to continue without an excessive rise in acidity2. 
349 Metabolic fingerprinting of chromosomal disorders
350 The polyol pathway appeared to be modified when comparing samples fromof  euploid and 
351 aneuploidy aneuploid chorionic villi with abnormal and normal chromosomes at the same 
352 gestational age. Metabolites such as D-sorbitol (vip scores>1), D-fructose (vip scores>1)  , D-
353 glucose (p<0.05) and pyruvic acid (vip scores>1) were found to be increased in the group 
354 ANEUPCHR group suggesting an over activation of the polyol pathway accompanied by a 
355 significant decrease of myo-inositol (p<0.05). 
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356 The increase of intracellular oxidative stress in CHR the group ANEUP, resulting fromby the 
357 activation of this pathway, was confirmed by HPLC analysis. A decrease of GSH (although not 
358 statistically significant), ascorbic acid (p<0.05) and an increase of dehydroascorbic acid (p<0.05) 
359 were also found. Despite the possible presence of oxidative stress discussed above, we didn’t 
360 observeddid not observe an increase of GSSG as we expected. The concentration of these 
361 metabolites confirms the increase of the intracellular oxidative stress and, consequently, the 
362 depletion of antioxidant defenses. Alterations in these pathways and the resultant excess oxidative 
363 stress, might represent be a primary pathological features feature in trisomies. 
364 These Our results showed a decrease of stearic and palmitic acid (p<0.05), in CHR Groupthe group 
365 ANEUP. FIn the growing fetus, fatty acids are necessary to maintain the fluidity, permeability and 
366 conformation of the membranes of the growing fetus and are essential as a source of energy and as 
367 precursors of important bioactive compounds such as the prostacyclins, prostaglandins, 
368 thromboxanes and leukotrienes. Apart from the overall placental supply of fatty acids, there is some 
369 evidence that the composition of the fatty acids may affect fetus fetal growth49. 
370 This analysis showed decreased levels of cholesterol  levels (p<0.05) in villi samples from the three 
371 chromosomal disorders studied here. Cholesterol is a major structural lipid of cell membranes, as 
372 well as the precursor of steroid hormones and bile acids. It was previously reported that cholesterol 
373 levels are significantly decreased in trisomies 18 and 21 compared to controls in plasma50 and 
374 amniocytes51. Our findings extend these results also to chorionic villi and likely reflect a disruption 
375 of the cholesterol pathway.
376 In conclusion, this study highlights a novel tool for studying metabolic alterations in placental tissue 
377 obtained during TA-CVS. Differences in metabolic concentrations were observed by gestational age 
378 and in the presence of aneuploidy. Finally, the metabolomics approach can may be able to 
379 discriminate the three common  trisomies based on the metabolic profile, but further analysis is 
380 necessary because the number of samples of all three trisomies was too low. This is Despite the new 
381 topic of this scientific work, this represents a preliminary study of metabolomics analysis in first 
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382 trimester TA-CVS samples due to the fact that the aneuploidies have a low incidence and further 
383 investigations are required. . Considering the low incidence of aneuploidies, further investigations 
384 are required before drawing conclusive comparisons between them.
385
386
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398 Tables
399 Table 1. Demographic and clinical features of patients with feti affected by chromosomal 
400 disorders and controls
Patients information 
N Age 
(Average ± 
NT
(Average ± 
CRL BMI 
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SD) SD) (Average ± SD) 
Controls 13 36.07±4.9 2.12±1.67 59.10±10.6 19.6 
Aneuploids 8 35.75±6.2 3.98±0.5 60.31±9.7 20.8 
401 Abbreviations. NT= Nuchal Translucency; CRL=Crown Rump Length, BMI= Body Mass Index.
402
403 Table 2. Panel of the most discriminant metabolites resulting from the multivariate analysis. In the 
404 table were included the VIP value (for the metabolites assayed with 1H-NMR and GC-MS), the p-
405 value (U-Mann Whitney test) with the respective correction for multiple comparisons (Benjamini-
406 Hochberg) for each metabolite.
Variables VIP value P-value Benjamini-Hochberg
Myo-Inositol 1.44293 0.01 0.036
Lactate 1.18766 0.1 -
Asparagine 1.87244 0.3 -
Glycerol 1,00025 0.4 -
Valine 1,52049 0.8 -
Leucine 1,11058 0.02 0.036
Isoleucine 1,49307 0.02 0.036
Fumarate 1.05523 0.32 -
Betaine 1,09841 0.16 -
N
M
R 
Acetate 1.02471 0.07 -
Pyruvate 1,96127 0.2 -
Homoserine 1,02222 0.5 -
Dehydroascorbic acid 1,19049 0.03 0.038
D-fructose 1,04314 0.07 -
1,5-anydro-D-sorbitol 1,08823 0.1 -
Glucose 1,22809 0.04 0.045
d-Sorbitol 1,18827 0.09 -
GC
-M
S 
Inositol 1,22475 0.08 -
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Palmitic acid 1,31942 0.02 0.036
Stearic acid 1,24499 0.05 NS
Cholesterol 1,57857 0.004 0.036
GSSH - 0.11 -
GSH - 0.23 -
HP
LC
 
Vit. C - 0.03 0.038
407
408 .
409 Figures
410 Figure 1. Identified compounds in chorionic villous samples analyzed with NMR and GC-MS.
411 Figure 1A. Identified compounds in NMR representative spectrum:1. Lipid1; 2. Isoleucine; 3. Leucine; 
412 4. Valine; 5. Lipid 2; 6. Lactate; 7. Threonine; 8. Alanine; 9. Lysine; 10. Thymine; 11. Acetate; 12. Proline; 
413 13. Glutamate; 14. Methionine; 15. Glutamate; 16. Pyroglutamate; 17. Glutamine; 18. Citrate; 19. aspartate; 
414 20. Sarcosine; 21. Asparagine; 22. Creatine; 23; Ornithine; 24. Ethanolamine; 25. Choline; 26 O-
415 phosphocholine; 27. Glycero-phosphocholine; 28. Glucose; 29. Betaine; 30. Myo-inositol; 31. Glycine; 32. 
416 Glycerol; 33. Glucitol; 34. Serine; 35. Fructose; 36. Nucleotides; 37. Mannose; 38. Uracil; 39. Fumarate; 40. 
417 Tyrosine; 41. Histidine; 42. η-Methylhistidine; 43. Phenylalanine; 44. Tryptophan; 45. Xanthine; 46. 
418 Hypoxanthine; 47. Formate.
419 B. Identified compounds in GC-MS representative chromatogram: 1. Pyruvic acid; 2. Lactic acid; 3. L-
420 valine; 4. L-alanine; 5. Leucine; 6. L-isoleucine; 7. Urea; 8. Ethanolamine; 9. L-serine; 10. Glycerol; 11. 
421 Glycine; 12. Succinic acid; 13. Fumaric acid; 14. Malic acid; 15. Homoserine; 16. Xylitol; 17. Ribitol; 18. 
422 Dehydroacorbic acid; 19. 1,5-anydro-D-sorbitol; 20. D-fructose; 21. D-glucose; 22. D-sorbitol; 23. D-
423 Mannitol; 24. Palmitic acid; 25. Inositol;, 26. Myo-inositol; 27. Stearic acid; 28. Cholesterol
424
425 Figure 2. Partial least square regression analysis and partial least square discriminant 
426 analysis.
427 Figure 2. A-B PLS regression analysis. Correlation between the metabolic profile of chorionic villous and 
428 CRL parameter of fetuses (points represent control samples (Group C) and the color indicated the respective 
429 CRL). The correlation analysis showed a R2 = 0.69 for the NMR analysis and R2 = 0.94 for the GC-MS 
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430 analysis.  C-D. PLS-DA models of samples with controls (Group C) and chromosomal disease (Group 
431 CHR). For the NMR analysis (C) statistical parameters were R2X=0.70, R2Y=0.65, Q2=0.30, while for the 
432 GC-MS analysis (D) were  R2X=0.60, R2Y=0.75, Q2=0.47. The models were then validated with the 
433 permutation test, (for the NMR R2 intercept = 0.428; Q2 intercept = -0.12, for the GC-MS R2 intercept = 
434 0.47; Q2 intercept = -0.6).
435
436 Figure 3. Comparison of select metabolites assayed in chorionic villous of fetuses with normal 
437 and abnormal karyotype.
438 Figure 3. The most important metabolites espressed by ranks with standard deviations as determined by 
439 different techniques. Group C were cases with normal chromosomes and Group CHR were cases with 
440 abnormal chromosomes. Statistical analysis were performed by Mann-Whitney U test. Metabolites 
441 differences between groups with p-value < 0.05 are indicated with the star. A)Analysis by NMR. B) Analysis 
442 by GC-MS C) Analysis by HPLC: box plots of the intracellular aminothiols such as GSH, GSSG and 
443 ascorbic acid. Data are expressed as area of peak to μg of proteins
444
445 Figure 4. Pathways analysis.
446 Figure 4. Most important pathways involved in placentas in cases with abnormal chromosomes. A) 
447 Summary of the most important pathways resulting from the analysis with Metaboanalyst: TCA cycle, 
448 pyruvate metabolism, glycolysis and gluconeogenesis, pentose phosphate pathway, glycine, serine and 
449 threonine metabolism were the most involved nets. B) Roles of the identified metabolites (green arrows 
450 means increase while blue arrows decrease) involved in the polyols pathway.
451
452 Figure 5. Partial least square discriminant analysis of trisomy 21, trisomy 18, trisomy 13 and 
453 control Group.
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454 Figure 5A. PLS-DA models of the three different chromosomal diseases (21, 18 and 13) and control group 
455 built with the GC-MS data (C). Statistical parameters were C vs Trisomy 21, R2X=0.62, R2Y=0.887, 
456 Q2=0.441, C vs Trisomy 18: R2X=0.509, R2Y=0.940, Q2=0.431, C vs Trisomy 13: R2X=0.557, R2Y=0.868, 
457 Q2=0.399 B. Venn diagram showing metabolite relationships between trisomy 21, trisomy 18 and trisomy 13 
458 is shown.
459
460
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Table 1. Demographic and clinical features of patients with fetuses affected by chromosomal 
disorders and controls
Patients information 
N Age (years) 
(Average ± 
SD) 
NT (mm)
(Average ± 
SD) 
CRL (mm)
(Average ± SD) 
BMI 
Euploids 13 36.07±4.9 2.12±1.67 59.10±10.6 19.6 
Aneuploids 8 35.75±6.2 3.98±0.5 60.31±9.7 20.8 
Abbreviations. NT= Nuchal Translucency; CRL=Crown Rump Length, BMI= Body Mass Index.
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Table 2. Panel of the most discriminant metabolites resulting from the multivariate analysis. In the 
table were included the VIP value (>1 for the metabolites assayed with 1H-NMR and GC-MS), the 
p-value (U-Mann Whitney test) with the respective correction for multiple comparisons (Benjamini-
Hochberg) for each metabolite. Metabolites resulting from the HPLC analysis did not show VIP 
values since they underwent only univariate analysis and not multivariate analysis.
Variables VIP value P-value Benjamini-Hochberg
Myo-Inositol 1.44293 0.01 0.036
Lactate 1.18766 0.1 -
Asparagine 1.87244 0.3 -
Glycerol 1,00025 0.4 -
Valine 1,52049 0.8 -
Leucine 1,11058 0.02 0.036
Isoleucine 1,49307 0.02 0.036
Fumarate 1.05523 0.32 -
Betaine 1,09841 0.16 -
N
M
R 
Acetate 1.02471 0.07 -
Pyruvate 1,96127 0.2 -
Homoserine 1,02222 0.5 -
Dehydroascorbic acid 1,19049 0.03 0.038
D-fructose 1,04314 0.07 -
1,5-anydro-D-sorbitol 1,08823 0.1 -
Glucose 1,22809 0.04 0.045
d-Sorbitol 1,18827 0.09 -
Inositol 1,22475 0.08 -
Palmitic acid 1,31942 0.02 0.036
Stearic acid 1,24499 0.05 NS
GC
-M
S 
Cholesterol 1,57857 0.004 0.036
GSSH - 0.11 -
GSH - 0.23 -
HP
LC
 
Vit. C - 0.03 0.038
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Figure 1. Identified compounds in chorionic villous samples analyzed with NMR and GC-MS. 
Figure 1A. Identified compounds in NMR representative spectrum:1. Lipid1; 2. Isoleucine; 3. Leucine; 4. 
Valine; 5. Lipid 2; 6. Lactate; 7. Threonine; 8. Alanine; 9. Lysine; 10. Thymine; 11. Acetate; 12. Proline; 
13. Glutamate; 14. Methionine; 15. Glutamate; 16. Pyroglutamate; 17. Glutamine; 18. Citrate; 19. 
aspartate; 20. Sarcosine; 21. Asparagine; 22. Creatine; 23; Ornithine; 24. Ethanolamine; 25. Choline; 26 
O-phosphocholine; 27. Glycero-phosphocholine; 28. Glucose; 29. Betaine; 30. Myo-inositol; 31. Glycine; 32. 
Glycerol; 33. Glucitol; 34. Serine; 35. Fructose; 36. Nucleotides; 37. Mannose; 38. Uracil; 39. Fumarate; 
40. Tyrosine; 41. Histidine; 42. η-Methylhistidine; 43. Phenylalanine; 44. Tryptophan; 45. Xanthine; 46. 
Hypoxanthine; 47. Formate. 
B. Identified compounds in GC-MS representative chromatogram: 1. Pyruvic acid; 2. Lactic acid; 3. L-valine; 
4. L-alanine; 5. Leucine; 6. L-isoleucine; 7. Urea; 8. Ethanolamine; 9. L-serine; 10. Glycerol; 11. Glycine; 
12. Succinic acid; 13. Fumaric acid; 14. Malic acid; 15. Homoserine; 16. Xylitol; 17. Ribitol; 18. 
Dehydroacorbic acid; 19. 1,5-anydro-D-sorbitol; 20. D-fructose; 21. D-glucose; 22. D-sorbitol; 23. D-
Mannitol; 24. Palmitic acid; 25. Inositol;, 26. Myo-inositol; 27. Stearic acid; 28. Cholesterol 
230x259mm (300 x 300 DPI) 
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Figure 2. Partial least square regression analysis and partial least square discriminant analysis. 
Figure 2. A-B PLS regression analysis. Correlation between the metabolic profile of chorionic villous and CRL 
parameter of fetuses (points represent control samples (group EUP) and the color indicated the respective 
CRL value).Y axis indicated the CRL value for each sample as reported by the clinical tests, while the 
predicitive CRL based on the metabolic profile is reported in the X axis. A)The correlation analysis showed a 
R2 = 0.69 for the NMR analysis and B) R2 = 0.94 for the GC-MS analysis.  C-D. PLS-DA models of samples 
with controls (black circles, group EUP) and chromosomal disease (white boxes, group ANEUP). For the NMR 
analysis (C) statistical parameters were R2X=0.70, R2Y=0.65, Q2=0.30, while for the GC-MS analysis (D) 
were  R2X=0.60, R2Y=0.75, Q2=0.47. The models were then validated with the permutation test, (for the 
NMR R2 intercept = 0.428; Q2 intercept = -0.12, for the GC-MS R2 intercept = 0.47; Q2 intercept = -0.6). 
254x190mm (300 x 300 DPI) 
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Figure 3. Comparison of select metabolites assayed in chorionic villous of fetuses with normal and abnormal 
karyotype. 
Figure 3. The most important metabolites expressed by ranks with standard deviations as determined by 
different techniques. Group EUP were cases with normal chromosomes and group ANEUP were cases with 
abnormal chromosomes. Statistical analysis was performed by Mann-Whitney U test. Metabolites differences 
between groups with p-value < 0.05 are indicated with the star. A) Analysis by NMR. B) Analysis by GC-MS 
C) Analysis by HPLC: box plots of the intracellular aminothiols such as GSH, GSSG and ascorbic acid. Data is 
expressed as area of peak to μg of proteins. 
258x352mm (150 x 150 DPI) 
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Figure 4. Pathways analysis. 
Figure 4. Most important pathways involved in placentas in cases with abnormal chromosomes. A) Summary 
of the most important pathways resulting from the analysis with Metaboanalyst: TCA cycle, pyruvate 
metabolism, glycolysis and gluconeogenesis, pentose phosphate pathway, glycine, serine and threonine 
metabolism were the most involved nets. The colours and the size of the circles indicate the importance of 
the pathway, evaluated through statistical parameters such as match status (metabolites resulted 
discriminant in our analysis and involved in the pathway), p-value and FDR correction (all parameters were 
reported in the supplementary material) calculated by the software Metaboanalyst. The red colour and the 
big size of the circles indicate the most important pathways. B) Roles of the identified metabolites (green 
arrows means increase while blue arrows decrease) involved in the polyols pathway. 
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Figure 5. Partial least square discriminant analysis of trisomy 21, trisomy 18, trisomy 13 and control Group. 
Figure 5A. PLS-DA models of the three different chromosomal diseases (21, n=4, 18, n=2 and 13, n=2) and 
control group built with the GC-MS data (C). Statistical parameters were group EUP vs Trisomy 21, 
R2X=0.62, R2Y=0.887, Q2=0.441, group EUP vs Trisomy 18: R2X=0.509, R2Y=0.940, Q2=0.431, group 
EUP vs Trisomy 13: R2X=0.557, R2Y=0.868, Q2=0.399 B. Venn diagram showing metabolite relationships 
between trisomy 21, trisomy 18 and trisomy 13. 
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